Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 3
1952 1
1972 1
1982 1
1992 1
1993 1
1998 3
2000 1
2001 1
2002 3
2003 3
2004 3
2005 4
2006 2
2007 2
2008 5
2009 2
2010 4
2011 2
2012 6
2013 7
2014 6
2015 11
2016 13
2017 14
2018 17
2019 24
2020 12
2021 24
2022 18
2023 15
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

192 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Kanakin
Page 1
[3D Genomics].
Razin SV, Ulianov SV, Gavrilov AA. Razin SV, et al. Mol Biol (Mosk). 2019 Nov-Dec;53(6):911-923. doi: 10.1134/S0026898419060156. Mol Biol (Mosk). 2019. PMID: 31876272 Free article. Review. Russian.
Acetylcholinesterase Inhibitors Toxicity.
Greathouse B, Zahra F, Brady MF. Greathouse B, et al. 2023 Apr 27. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2023 Apr 27. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 30571049 Free Books & Documents.
More recently the has been the use of "Novichok", or newcomer agents, that are more potent than VX in the attempted assassinations of Sergei Skripal and Alexei Navalny. All the G agents, V agents, and Novichok agents act by inhibition of acetylcholinesterase....
More recently the has been the use of "Novichok", or newcomer agents, that are more potent than VX in the attempted assassinations of Ser …
Genomic mutation landscape of skin cancers from DNA repair-deficient xeroderma pigmentosum patients.
Yurchenko AA, Rajabi F, Braz-Petta T, Fassihi H, Lehmann A, Nishigori C, Wang J, Padioleau I, Gunbin K, Panunzi L, Morice-Picard F, Laplante P, Robert C, Kannouche PL, Menck CFM, Sarasin A, Nikolaev SI. Yurchenko AA, et al. Nat Commun. 2023 May 4;14(1):2561. doi: 10.1038/s41467-023-38311-0. Nat Commun. 2023. PMID: 37142601 Free PMC article.
Xeroderma pigmentosum (XP) is a genetic disorder caused by mutations in genes of the Nucleotide Excision Repair (NER) pathway (groups A-G) or in Translesion Synthesis DNA polymerase eta (V). XP is associated with an increased skin cancer risk, reaching, for some groups, se …
Xeroderma pigmentosum (XP) is a genetic disorder caused by mutations in genes of the Nucleotide Excision Repair (NER) pathway (groups A-G) o …
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.
Kelly K, Altorki NK, Eberhardt WE, O'Brien ME, Spigel DR, Crinò L, Tsai CM, Kim JH, Cho EK, Hoffman PC, Orlov SV, Serwatowski P, Wang J, Foley MA, Horan JD, Shepherd FA. Kelly K, et al. J Clin Oncol. 2015 Dec 1;33(34):4007-14. doi: 10.1200/JCO.2015.61.8918. Epub 2015 Aug 31. J Clin Oncol. 2015. PMID: 26324372 Clinical Trial.
Among the 161 patients (16.5%) in the EGFRm-positive subgroup, DFS favored erlotinib (median, 46.4 v 28.5 months; hazard ratio, 0.61; 95% CI, 0.38 to 0.98; P = .039), but this was not statistically significant because of the hierarchical testing procedure. ...
Among the 161 patients (16.5%) in the EGFRm-positive subgroup, DFS favored erlotinib (median, 46.4 v 28.5 months; hazard ratio, 0.61; …
Rad regulation of Ca(V)1.2 channels controls cardiac fight-or-flight response.
Papa A, Zakharov SI, Katchman AN, Kushner JS, Chen BX, Yang L, Liu G, Jimenez AS, Eisert RJ, Bradshaw GA, Dun W, Ali SR, Rodriques A, Zhou K, Topkara V, Yang M, Morrow JP, Tsai EJ, Karlin A, Wan E, Kalocsay M, Pitt GS, Colecraft HM, Ben-Johny M, Marx SO. Papa A, et al. Nat Cardiovasc Res. 2022 Nov;1(11):1022-1038. doi: 10.1038/s44161-022-00157-y. Epub 2022 Nov 14. Nat Cardiovasc Res. 2022. PMID: 36424916 Free PMC article.
Interim Safety Profile From the Feasibility Study of the BrainGate Neural Interface System.
Rubin DB, Ajiboye AB, Barefoot L, Bowker M, Cash SS, Chen D, Donoghue JP, Eskandar EN, Friehs G, Grant C, Henderson JM, Kirsch RF, Marujo R, Masood M, Mernoff ST, Miller JP, Mukand JA, Penn RD, Shefner J, Shenoy KV, Simeral JD, Sweet JA, Walter BL, Williams ZM, Hochberg LR. Rubin DB, et al. Neurology. 2023 Mar 14;100(11):e1177-e1192. doi: 10.1212/WNL.0000000000201707. Epub 2023 Jan 13. Neurology. 2023. PMID: 36639237 Free PMC article. Clinical Trial.
25th Annual Computational Neuroscience Meeting: CNS-2016.
Sharpee TO, Destexhe A, Kawato M, Sekulić V, Skinner FK, Wójcik DK, Chintaluri C, Cserpán D, Somogyvári Z, Kim JK, Kilpatrick ZP, Bennett MR, Josić K, Elices I, Arroyo D, Levi R, Rodriguez FB, Varona P, Hwang E, Kim B, Han HB, Kim T, McKenna JT, Brown RE, McCarley RW, Choi JH, Rankin J, Popp PO, Rinzel J, Tabas A, Rupp A, Balaguer-Ballester E, Maturana MI, Grayden DB, Cloherty SL, Kameneva T, Ibbotson MR, Meffin H, Koren V, Lochmann T, Dragoi V, Obermayer K, Psarrou M, Schilstra M, Davey N, Torben-Nielsen B, Steuber V, Ju H, Yu J, Hines ML, Chen L, Yu Y, Kim J, Leahy W, Shlizerman E, Birgiolas J, Gerkin RC, Crook SM, Viriyopase A, Memmesheimer RM, Gielen S, Dabaghian Y, DeVito J, Perotti L, Kim AJ, Fenk LM, Cheng C, Maimon G, Zhao C, Widmer Y, Sprecher S, Senn W, Halnes G, Mäki-Marttunen T, Keller D, Pettersen KH, Andreassen OA, Einevoll GT, Yamada Y, Steyn-Ross ML, Alistair Steyn-Ross D, Mejias JF, Murray JD, Kennedy H, Wang XJ, Kruscha A, Grewe J, Benda J, Lindner B, Badel L, Ohta K, Tsuchimoto Y, Kazama H, Kahng B, Tam ND, Pollonini L, Zouridakis G, Soh J, Kim D, Yoo M, Palmer SE, Culmone V, Bojak I, Ferrario A, Merrison-Hort R, Borisyuk R, Kim CS, Tezuka T, Joo P, Rho YA, Burt… See abstract for full author list ➔ Sharpee TO, et al. BMC Neurosci. 2016 Aug 18;17 Suppl 1(Suppl 1):54. doi: 10.1186/s12868-016-0283-6. BMC Neurosci. 2016. PMID: 27534393 Free PMC article.
Tran, Alex Fornito P162 Emergence of narrowband LFP oscillations from completely asynchronous activity during seizures and high-frequency oscillations Stephen V. Gliske, William C. Stacey, Eugene Lim, Katherine A. Holman, Christian G. ...Pragathi Priyadharsini, Hima Mehta, …
Tran, Alex Fornito P162 Emergence of narrowband LFP oscillations from completely asynchronous activity during seizures and high-frequency os …
Targeted Magnetic Nanotheranostics of Cancer.
Belyanina I, Kolovskaya O, Zamay S, Gargaun A, Zamay T, Kichkailo A. Belyanina I, et al. Molecules. 2017 Jun 12;22(6):975. doi: 10.3390/molecules22060975. Molecules. 2017. PMID: 28604617 Free PMC article. Review.
Heat Stress-Induced Transcriptional Repression.
Kantidze OL, Velichko AK, Razin SV. Kantidze OL, et al. Biochemistry (Mosc). 2015 Aug;80(8):990-3. doi: 10.1134/S0006297915080039. Biochemistry (Mosc). 2015. PMID: 26547066 Review.
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M. Sequist LV, et al. J Clin Oncol. 2013 Sep 20;31(27):3327-34. doi: 10.1200/JCO.2012.44.2806. Epub 2013 Jul 1. J Clin Oncol. 2013. PMID: 23816960 Corrected and republished. Clinical Trial.
192 results